OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades above our $1,329.60 fair value estimate, 3.70% revenue growth.
Read at
$2,659.20
64.93 P/E · 51.90 fwd
Our fair value
$1,329.60
50% premium
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard · AAOIFI
Used by most halal investing apps
✓ PASSES
Our stricter standard · asset-based
The one Titan applies
✓ PASSES
What these two standards are, and how they differ →
-
Business activity
Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
-
Debt load
Interest-bearing debt is just 7.5% of its assets, well under the one-third ceiling — it does not run on borrowed money.
Pass
-
Interest-bearing cash
Cash held in interest-bearing accounts and securities is 1.5% of assets, under the one-third limit.
Pass
-
Receivables
Money owed to the company is 14.2% of assets, under the 49% limit.
Pass
-
Revenue purity
Only 0.1% of revenue comes from non-compliant sources — under the 5% line.
Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Why it gives us pause
At 51.9x forward earnings, the price already runs ahead of the business. It trades 50% above our $1,329.60 fair value, so you would be buying at a premium, not a discount.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
JOURNAL
The dated journal · newest first, never edited
2026-07-28
Markup $2,659.20
+0.0% Entry 12
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27
Markup $2,659.20
+0.0% Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26
Markup $2,659.20
+0.0% Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25
Markup $2,659.20
+0.0% Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24
Markup $2,659.20
+0.0% Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23
Markup $2,659.20
+0.0% Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22
Markup $2,659.20
+0.0% Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21
Markup $2,659.20
+0.0% Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675.
2026-07-18
Markup $2,659.20
+0.0% Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675.
2026-07-17
Markup $2,659.20
+0.0% Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (93). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (34 analysts) rates it hold, with a mean price target of $2675.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.